Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis.

Blixt O, Bueti D, Burford B, Allen D, Julien S, Hollingsworth M, Gammerman A, Fentiman I, Taylor-Papadimitriou J, Burchell JM.

Breast Cancer Res. 2011 Mar 8;13(2):R25. doi: 10.1186/bcr2841.

2.

TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells.

Zhang Y, Luo F, Cai Y, Liu N, Wang L, Xu D, Chu Y.

J Immunol. 2011 Feb 15;186(4):1963-9. doi: 10.4049/jimmunol.1002320.

3.

MUC1 immunotherapy.

Beatson RE, Taylor-Papadimitriou J, Burchell JM.

Immunotherapy. 2010 May;2(3):305-27. doi: 10.2217/imt.10.17. Review.

PMID:
20635898
4.

Differential induction of innate immune responses by synthetic lipid a derivatives.

Gaekwad J, Zhang Y, Zhang W, Reeves J, Wolfert MA, Boons GJ.

J Biol Chem. 2010 Sep 17;285(38):29375-86. doi: 10.1074/jbc.M110.115204.

5.

A year of successful cancer vaccines points to a path forward.

Morse MA, Whelan M.

Curr Opin Mol Ther. 2010 Feb;12(1):11-3. Review.

PMID:
20140811
6.

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.

Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM.

Clin Cancer Res. 2009 Sep 1;15(17):5323-37. doi: 10.1158/1078-0432.CCR-09-0737.

7.

Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model.

Julien S, Picco G, Sewell R, Vercoutter-Edouart AS, Tarp M, Miles D, Clausen H, Taylor-Papadimitriou J, Burchell JM.

Br J Cancer. 2009 Jun 2;100(11):1746-54. doi: 10.1038/sj.bjc.6605083.

8.

Toll-like receptors and cancer.

Rakoff-Nahoum S, Medzhitov R.

Nat Rev Cancer. 2009 Jan;9(1):57-63. doi: 10.1038/nrc2541. Review.

PMID:
19052556
9.

Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes.

Ninkovic T, Kinarsky L, Engelmann K, Pisarev V, Sherman S, Finn OJ, Hanisch FG.

Mol Immunol. 2009 Nov;47(1):131-40. doi: 10.1016/j.molimm.2008.09.032.

10.

STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells.

Cohen PA, Koski GK, Czerniecki BJ, Bunting KD, Fu XY, Wang Z, Zhang WJ, Carter CS, Awad M, Distel CA, Nagem H, Paustian CC, Johnson TD, Tisdale JF, Shu S.

Blood. 2008 Sep 1;112(5):1832-43. doi: 10.1182/blood-2007-12-130138.

11.

Mucin-type O-glycosylation and its potential use in drug and vaccine development.

Tarp MA, Clausen H.

Biochim Biophys Acta. 2008 Mar;1780(3):546-63. Review.

PMID:
17988798
12.

Robust immune responses elicited by a fully synthetic three-component vaccine.

Ingale S, Wolfert MA, Gaekwad J, Buskas T, Boons GJ.

Nat Chem Biol. 2007 Oct;3(10):663-7.

13.

O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes.

Ninkovic T, Hanisch FG.

J Immunol. 2007 Aug 15;179(4):2380-8.

14.

MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.

Mukherjee P, Pathangey LB, Bradley JB, Tinder TL, Basu GD, Akporiaye ET, Gendler SJ.

Vaccine. 2007 Feb 19;25(9):1607-18.

15.

Synthesis of glyco(lipo)peptides by liposome-mediated native chemical ligation.

Ingale S, Buskas T, Boons GJ.

Org Lett. 2006 Dec 7;8(25):5785-8.

PMID:
17134272
16.

Targeting antigens to dendritic cells in vivo.

Tacken PJ, Torensma R, Figdor CG.

Immunobiology. 2006;211(6-8):599-608. Review.

PMID:
16920498
17.

Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine.

Hanisch FG, Ninkovic T.

Curr Protein Pept Sci. 2006 Aug;7(4):307-15. Review.

PMID:
16918445
18.

Synthesis and structural model of an alpha(2,6)-sialyl-t glycosylated MUC1 eicosapeptide under physiological conditions.

Dziadek S, Griesinger C, Kunz H, Reinscheid UM.

Chemistry. 2006 Jun 23;12(19):4981-93.

PMID:
16642533
19.
20.

Malignancy-induced autoimmunity to MUC1: initial antibody characterization.

Graves CR, Robertson JF, Murray A, Price MR, Chapman CJ.

J Pept Res. 2005 Dec;66(6):357-63.

PMID:
16316451
Items per page

Supplemental Content

Support Center